Uveitis
ASTUTE: Adalimumab vs placebo as add-on to Standard Therapy for autoimmune Uveitis: Tolerability, Effectiveness, and cost-effectiveness: a randomized controlled trial.
Eye condition/Study type:
Uveitis
Principal Investigator:
Miss Srilakshmi Sharma
Autoimmune uveitis is a rare condition where the immune system damages the retina, causing sight loss due to inflammation, blood vessel damage, or fluid leakage. Two in 10,000 people are at risk of serious vision loss. Treatment typically involves steroids, but many patients do not respond or tolerate them, and long-term steroid use carries risks. Adalimumab, which targets the chemical TNF-alpha, has shown promise for treating uveitis but can have serious side effects. The ASTUTE Trial aims to identify patients who benefit most from adalimumab. Participants will receive adalimumab for 16 weeks before entering a randomized trial to assess its effectiveness and cost-effectiveness.
https://studies.ouh.nhs.uk/project_detail/7587/
Currently recruiting. If interested, please contact via email ERGO@ouh.nhs.uk
Molecular Pathways of Ocular Inflammatory Disease – Towards a Mechanistic Understanding of Ocular Inflammation.
Eye condition/Study type:
Uveitis
Principal Investigator:
Miss Srilakshmi Sharma
Ocular inflammatory disease encompasses infectious and immune-mediated conditions causing inflammation in various eye parts, affecting 1 in 5000 individuals and ranking as the third leading cause of blindness in the West. Uveitis, a key subtype, involves inflammation in the uveal tract (iris, ciliary body, and choroid). It can be infectious or non-infectious, with anterior uveitis being the most prevalent, affecting nearly 50 per 100,000 people and causing vision impairment and pain. This study aims to analyse tissue and fluid samples from uveitis patients, using flow cytometry, protein analysis, and single-cell RNA sequencing to uncover inflammation causes and identify potential therapeutic targets.
https://studies.ouh.nhs.uk/project_detail/8524/
Currently recruiting. If interested, please contact via email ERGO@ouh.nhs.uk